What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Tadeusz Robak focuses on Internal medicine, Gastroenterology, Leukemia, Surgery and Immunology.
Internal medicine is closely attributed to Oncology in his work.
His research on Gastroenterology also deals with topics like
- Phases of clinical research which intersects with area such as Multiple myeloma,
- Refractory that intertwine with fields like Moxetumomab pasudotox.
The study incorporates disciplines such as Myeloid, Cladribine and Randomized controlled trial in addition to Leukemia.
The various areas that he examines in his Surgery study include Toxicity and Bortezomib.
His Immunology study deals with Genotype intersecting with Genetic predisposition.
His most cited work include:
- Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. (991 citations)
- Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia (757 citations)
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study (712 citations)
What are the main themes of his work throughout his whole career to date?
Tadeusz Robak mostly deals with Internal medicine, Chronic lymphocytic leukemia, Immunology, Oncology and Gastroenterology.
His Internal medicine study frequently links to adjacent areas such as Surgery.
His research in Chronic lymphocytic leukemia focuses on subjects like Cancer research, which are connected to Apoptosis.
His Oncology research is multidisciplinary, relying on both Mantle cell lymphoma, Chemotherapy, Ibrutinib and Multiple myeloma.
His Gastroenterology study integrates concerns from other disciplines, such as Adverse effect and Neutropenia.
His Cladribine study combines topics in areas such as Mitoxantrone, Cytarabine, Regimen, Pentostatin and Pharmacology.
He most often published in these fields:
- Internal medicine (58.54%)
- Chronic lymphocytic leukemia (31.94%)
- Immunology (30.25%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (58.54%)
- Oncology (26.73%)
- Chronic lymphocytic leukemia (31.94%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Oncology, Chronic lymphocytic leukemia, Rituximab and Ibrutinib.
His Internal medicine course of study focuses on Gastroenterology and Minimal residual disease.
His biological study spans a wide range of topics, including Chlorambucil, Phases of clinical research, Mantle cell lymphoma, Ofatumumab and Venetoclax.
Tadeusz Robak has included themes like Fludarabine and Chemoimmunotherapy in his Ofatumumab study.
Tadeusz Robak combines subjects such as Hematology and Cancer research with his study of Chronic lymphocytic leukemia.
His Rituximab research includes elements of Follicular lymphoma, Hairy cell leukemia, Moxetumomab pasudotox and Surgery.
Between 2016 and 2021, his most popular works were:
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (392 citations)
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia (318 citations)
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome (185 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Tadeusz Robak spends much of his time researching Internal medicine, Oncology, Chronic lymphocytic leukemia, Rituximab and Leukemia.
His Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology.
Tadeusz Robak interconnects Venetoclax, Surgery, Ofatumumab and Chemoimmunotherapy in the investigation of issues within Oncology.
He usually deals with Chronic lymphocytic leukemia and limits it to topics linked to Cancer and Quality of life and Btk inhibitors.
His Rituximab research incorporates themes from Mantle cell lymphoma and Progression-free survival.
His studies in Leukemia integrate themes in fields like Regimen and Myeloid leukemia.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
